Twitter's Favorite Biotech and Pharma Stocks
Brian Orelli, The Motley Fool - Motley Fool - Tue Dec 16, 8:21AM CST
Mark Schoenebaum, the biotech and pharmaceutical analyst at Evercore ISI, asked the Twittersphere for their favorite drug stocks going into next year. What's your favorite stock for 2015 in biotech or Pharma? — Mark Schoenebaum...
BLUE: 88.76 (+3.23), BMRN: 88.18 (+0.89), TGTX: 16.03 (+0.33), BMY: 59.15 (-0.01), MACK: 10.91 (+0.36), FMI: 23.99 (-0.10), RNA: 18.76 (+0.10), GWPH: 68.08 (+1.82), SRPT: 13.88 (+0.47), MRK: 57.46 (+0.25), NLNK: 39.08 (+1.36), ICPT: 151.49 (+5.85), THLD: 2.93 (+0.01), CEMP: 20.66 (+0.78), NVS: 93.91 (+0.66)
Foundation Medicine to Be Added to NASDAQ Biotechnology Index
Business Wire - Tue Dec 16, 5:30AM CST
Foundation Medicine, Inc. (NASDAQ:FMI) today announced that the Company will be added to the NASDAQ Biotechnology Index (NASDAQ: NBI), effective prior to the market open on Monday, December 22, 2014.
FMI: 23.99 (-0.10), IBB: 299.80 (+5.12)
Nasdaq makes annual changes to Biotechnology Index
Seeking Alpha - at Seeking Alpha - Mon Dec 15, 11:36AM CST
TTPH: 38.86 (+0.53), ZSPH: 43.93 (+1.77), AMRN: 0.99 (unch), OPHT: 44.93 (+1.06), AERI: 29.49 (+1.23), ASPX: 49.93 (-0.10), CNCE: 11.76 (+0.11), ICEL: 5.74 (-0.18), GWPH: 68.08 (+1.82), AUXL: 34.40 (+0.18), RTRX: 12.92 (+0.19), RCPT: 122.05 (+4.05), AAVL: 47.30 (-1.20), AKBA: 11.23 (-0.31), EXPR: 14.96 (+0.32), RARE: 45.17 (-0.56), RLYP: 30.35 (-0.22), PETX: 17.05 (+0.42), ENTA: 49.04 (+0.06), RDUS: 37.17 (+0.11), CARA: 9.78 (+0.02), FLML: 17.01 (-0.98), ALIM: 5.43 (-0.06), ANIP: 55.24 (+1.79), ICPT: 151.49 (+5.85), RVNC: 16.65 (+0.42), POZN: 7.86 (+0.07), FPRX: 26.12 (+0.07), ZFGN: 30.99 (+0.67), CRIS: 1.29 (+0.04), QLTI: 3.72 (+0.08), PCYC: 121.84 (+1.15), PTX: 9.05 (+0.28), CLDN: 18.54 (+0.85), RIGL: 2.22 (+0.02), HPTX: 21.91 (-0.08), AMPH: 11.74 (-0.09), INO: 9.11 (-0.09), VSAR: 22.25 (-0.11), FMI: 23.99 (-0.10), TBPH: 14.84 (+0.20), XLRN: 38.80 (+0.80), MGNX: 33.00 (+0.34), INSM: 15.29 (+0.15), ONTX: 3.82 (+0.06), ALDR: 25.67 (+0.43), SAGE: 38.13 (-0.75), KITE: 51.96 (+0.45), CGEN: 8.58 (-0.17), FOLD: 7.94 (+0.06), KPTI: 37.78 (+1.28)
Annual Changes to the NASDAQ Biotechnology Index
GlobeNewswire - Mon Dec 15, 6:10AM CST
The NASDAQ OMX Group, Inc. (Nasdaq:NDAQ) today announced the results of the annual re-ranking of the NASDAQ Biotechnology Index (Nasdaq:NBI), which will become effective prior to market open on Monday, December 22, 2014.
TTPH: 38.86 (+0.53), ZSPH: 43.93 (+1.77), AMRN: 0.99 (unch), OPHT: 44.93 (+1.06), AERI: 29.49 (+1.23), ASPX: 49.93 (-0.10), CNCE: 11.76 (+0.11), ICEL: 5.74 (-0.18), GWPH: 68.08 (+1.82), AUXL: 34.40 (+0.18), RTRX: 12.92 (+0.19), RCPT: 122.05 (+4.05), AAVL: 47.30 (-1.20), AKBA: 11.23 (-0.31), EXPR: 14.96 (+0.32), RARE: 45.17 (-0.56), ZGNX: 1.20 (+0.04), RLYP: 30.35 (-0.22), PETX: 17.05 (+0.42), ENTA: 49.04 (+0.06), RDUS: 37.17 (+0.11), CARA: 9.78 (+0.02), FLML: 17.01 (-0.98), ALIM: 5.43 (-0.06), ANIP: 55.24 (+1.79), ICPT: 151.49 (+5.85), RVNC: 16.65 (+0.42), POZN: 7.86 (+0.07), NDAQ: 48.74 (-0.40), FPRX: 26.12 (+0.07), CRIS: 1.29 (+0.04), ZFGN: 30.99 (+0.67), QLTI: 3.72 (+0.08), PCYC: 121.84 (+1.15), PTX: 9.05 (+0.28), CLDN: 18.54 (+0.85), RIGL: 2.22 (+0.02), HPTX: 21.91 (-0.08), AMPH: 11.74 (-0.09), INO: 9.11 (-0.09), VSAR: 22.25 (-0.11), FMI: 23.99 (-0.10), TBPH: 14.84 (+0.20), XLRN: 38.80 (+0.80), MGNX: 33.00 (+0.34), INSM: 15.29 (+0.15), ONTX: 3.82 (+0.06), ALDR: 25.67 (+0.43), SAGE: 38.13 (-0.75), KITE: 51.96 (+0.45), CGEN: 8.58 (-0.17), FOLD: 7.94 (+0.06), KPTI: 37.78 (+1.28)
FoundationOne(R) Identifies Clinically Relevant Genomic Alterations in Patients with Advanced Breast Cancers
Business Wire - Tue Dec 09, 8:01AM CST
Foundation Medicine, Inc. (NASDAQ:FMI) today announced new data further demonstrating the clinical utility of FoundationOne(R) across several types of breast cancer, including metastatic and inflammatory breast cancer. Collectively, these studies support the use of comprehensive genomic profiling to identify distinct genomic alterations that may further tailor treatment options and result in improved outcomes for patients with breast cancer. These data are being presented by Foundation Medicine and its collaborators during the 2014 San Antonio Breast Cancer Symposium.
FMI: 23.99 (-0.10)
New Clinical Data Supports the Use of FoundationOne(R) Heme to Enable Informed Treatment Decisions in a Wide Range of Hematologic Malignancies
Business Wire - Tue Dec 09, 5:30AM CST
Foundation Medicine, Inc. (NASDAQ:FMI) today announced new data demonstrating that FoundationOne(R) Heme, developed in collaboration with Memorial Sloan Kettering Cancer Center, provides critical genomic information that can impact prognosis, influence therapeutic strategy and even refine conventional pathologic diagnosis in patients with a wide range of hematologic malignancies. Collectively, these data highlight the potentially transformative impact of FoundationOne Heme across all aspects of cancer care. These findings were presented in two posters and an oral presentation at the American Society of Hematology Annual Meeting in San Francisco.
FMI: 23.99 (-0.10)
Treatment for Relapsed Multiple Myeloma Patients Guided by FoundationOne(R) Heme Results in Promising Clinical Activity
Business Wire - Mon Dec 08, 12:00PM CST
Foundation Medicine, Inc. (NASDAQ:FMI) today announced new data demonstrating that its comprehensive genomic profile, FoundationOne(R) Heme, identified genomic alterations in patients with heavily pre-treated multiple myeloma that informed treatment with trametinib, an FDA-approved targeted therapeutic agent(1). Notably, 68% of total patients who underwent treatment based on results provided by FoundationOne Heme experienced clinical benefit, supporting the clinical utility of this test in patients with refractory or relapsed multiple myeloma for whom other treatment options have largely been exhausted.
FMI: 23.99 (-0.10)
Foundation Medicine and Collaborators to Present New Clinical Data on the Application of FoundationOne(R) in Breast Cancer at the 2014 San Antonio Breast Cancer Symposium
Business Wire - Wed Dec 03, 5:30AM CST
Foundation Medicine, Inc. (NASDAQ:FMI) today announced that eight abstracts highlighting new clinical data on the application of FoundationOne(R) in patients with breast cancer will be presented at the 37th Annual San Antonio Breast Cancer Symposium (SABCS) taking place December 9-13, 2014, at the Henry B. Gonzalez Convention Center in San Antonio, Texas.
FMI: 23.99 (-0.10)
Foundation Medicine Appoints David J. Daly as Chief Commercial Officer
Business Wire - Tue Dec 02, 4:30PM CST
Foundation Medicine, Inc. (NASDAQ:FMI) today announced the appointment of David J. Daly to the role of chief commercial officer. Mr. Daly brings more than 25 years of proven commercial experience in both emerging and Fortune 500 clinical diagnostics and oncology companies to his new role leading Foundation Medicine's commercial organization. Mr. Daly will report to president and chief executive officer, Michael J. Pellini, M.D.
FMI: 23.99 (-0.10)
Foundation Medicine and Flatiron Health Collaborate to Develop First-in-Class Data Platform to Accelerate Precision Medicine for Cancer
Business Wire - Tue Dec 02, 5:30AM CST
Foundation Medicine, Inc. (NASDAQ:FMI) and Flatiron Health today announced a strategic collaboration to develop a unique, proprietary cloud-based information platform combining genomic and clinical treatment and outcomes data to significantly advance the field of precision medicine for cancer.
FMI: 23.99 (-0.10)
Foundation Medicine to Present at the Piper Jaffray Healthcare Conference
Business Wire - Tue Nov 25, 5:30AM CST
Foundation Medicine, Inc. (NASDAQ:FMI) today announced Steven J. Kafka, Ph.D., chief operating officer, is scheduled to present at the Piper Jaffray Healthcare Conference on Wednesday, December 3, 2014, at 3:30 p.m. E.T. in New York City.
FMI: 23.99 (-0.10)
Foundation Medicine's Novel Companion Diagnostic Test, Developed in Collaboration with Clovis Oncology, Identifies Expanded Subgroup of Cancer Patients with the Potential to Respond to Clovis Oncology's PARP inhibitor, Rucaparib
Business Wire - Wed Nov 19, 5:05PM CST
Foundation Medicine, Inc. (NASDAQ: FMI) today announced the presentation of new data from its ongoing collaboration with Clovis Oncology (NASDAQ: CLVS) to develop a novel companion diagnostic test to identify patients who have the potential to benefit from rucaparib, Clovis Oncology's poly (ADP-ribose) polymerase inhibitor (PARPi). These new data suggest that Foundation Medicine's novel companion diagnostic can identify both BRCA-mutant patients and non BRCA-mutant patients who are more likely to benefit from rucaparib than patients who are biomarker negative.
FMI: 23.99 (-0.10), CLVS: 54.58 (+0.43)
Foundation Medicine Winning Increased Insurance Coverage for Genetic Cancer Tests
at The Street - Wed Nov 19, 10:17AM CST
Coverage decisions are still likely to slowly build over time but it is a clear positive that we are seeing the early adopters start to reimburse for Foundation's cancer tests.
FMI: 23.99 (-0.10)
Foundation Medicine to Present at Upcoming Investor Conferences
Business Wire - Thu Nov 13, 5:30AM CST
Foundation Medicine, Inc. (NASDAQ:FMI) today announced that members of the company's management team will present at the following upcoming investor conferences:
FMI: 23.99 (-0.10)
The Robert H. Lurie Comprehensive Cancer Center of Northwestern University and the Northwestern Medicine Developmental Therapeutics Institute Partner with Foundation Medicine to Launch Innovative Clinical Translation Program
Business Wire - Wed Nov 12, 7:01AM CST
The Robert H. Lurie Comprehensive Cancer Center of Northwestern University (Lurie Cancer Center) and the Northwestern Medicine Developmental Therapeutics Institute (NMDTI) today announced the initiation of a new clinical translation program with Foundation Medicine, Inc. (NASDAQ: FMI) designed to assist in the development of oncology therapeutics and further expand the clinical utility of Foundation Medicine's comprehensive genomic profiling technologies.
FMI: 23.99 (-0.10)
Foundation Medicine's (FMI) CEO Michael Pellini on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Sun Nov 09, 5:36AM CST
FMI: 23.99 (-0.10)
Foundation Medicine Slumps: FMI Tumbles 9.6% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 7:59AM CST
Foundation Medicine has been witnessing a flat trend in its current year earnings estimate and its share price has been falling for past 24 hours
ABMD: 38.46 (+0.13), DXCM: 54.94 (+0.99), FMI: 23.99 (-0.10), ANGO: 19.19 (+0.33)
Foundation Medicine and Collaborators to Present New Clinical Data on FoundationOne(R) Heme at the American Society of Hematology Annual Meeting
Business Wire - Thu Nov 06, 9:58AM CST
Foundation Medicine, Inc. (NASDAQ:FMI) today announced that 12 abstracts highlighting new clinical data on FoundationOne(R) Heme will be presented at the 56th American Society of Hematology (ASH) Annual Meeting and Exposition taking place December 6-9, 2014, at the Moscone Center in San Francisco.
FMI: 23.99 (-0.10)
"Don't Guess. Test." Campaign Aims to Educate Patients About Comprehensive Genomic Testing in Lung Cancer
Business Wire - Thu Nov 06, 7:02AM CST
The Bonnie J. Addario Lung Cancer Foundation (ALCF), in collaboration with Foundation Medicine and Friends of Cancer Research, and in partnership with many advocacy organizations, today launched the "Don't Guess. Test." campaign to expand awareness and educate patients about precision medicine and the importance of comprehensive genomic testing in lung cancer. Through extensive grassroots and social media efforts, the campaign's 16 lung cancer advocacy organizations are working throughout the country on this important collaborative initiative. Campaign partners include: American Lung Association, Cancer Care, Caring Ambassadors Program, Dusty Joy Foundation, Free Me, Free to Breathe, Lung Cancer Initiative of North Carolina, Lung Cancer Alliance, Lung Cancer Circle of Hope, Lung Cancer Foundation of America, Rexanna's Foundation, United Against Lung Cancer, Upstage Lung Cancer and We Wish Foundation.
FMI: 23.99 (-0.10)
Foundation Medicine beats Street 3Q forecasts
Automated Insights - Wed Nov 05, 4:39PM CST
CAMBRIDGE, Mass. (AP) _ Foundation Medicine Inc. (FMI) on Wednesday reported a third-quarter loss of $13 million.
FMI: 23.99 (-0.10)